| 產品編號 | bs-2029R-Cy5 |
| 英文名稱 | Rabbit Anti-Morphine/Cy5 Conjugated antibody |
| 中文名稱 | Cy5標記的嗎啡抗體 |
| 別 名 | Morphine 6. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 產品類型 | 小分子抗體 |
| 研究領域 | 免疫學 神經生物學 藥物及化合物 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | |
| 產品應用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 0.75883kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Morphine |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: Morphine is thought to produce reinforcement phenomena via stimulation of mu, delta, and kappa opioid receptors that regulate stress perception, pain control, reward behavior, and neurohormone secretion in reward-relevant brain systems. It has the highest affinity for mu, followed by delta and kappa. Rapid activation of the mu opioid receptor by morphine results in a euphoric phenotype, thus conferring the reinforcing effects of the drug. This activation is accompanied by extracellular dopamine release, which alters several events related to the cAMP signal transduction pathway. Of particular significance is that CREB seems to be modified by morphine, thereby affecting addictive behavioral phenomena, such as withdrawal symptoms. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
